BFRG BULLFROG AI HOLDINGS

BullFrog AI to Present at Benzinga All Access Event on October 20

BullFrog AI to Present at Benzinga All Access Event on October 20

GAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, Founder and CEO of BullFrog AI, will present during Benzinga's All Access investor event on Friday, October 20, 2023, at 11:00 a.m. ET.

Webcast:

A live video webcast will be available using the link above - an archived replay will be made available after the live event on the . For more information on Benzinga All Access, please contact your Benzinga representative.

About BullFrog AI

BullFrog AI is a technology-enabled drug development company that creates and analyzes networks of biological, clinical, and real-world data spanning from early discovery to late-stage clinical trials. Through its partnerships with leading research institutions, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.

For more information visit BullFrog AI at

Website:

LinkedIn:

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Investor Contact:

Dave Gentry

RedChip Companies, Inc.



800-733-2447

SOURCE: BullFrog AI Holdings, Inc.



EN
18/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BULLFROG AI HOLDINGS

 PRESS RELEASE

BullFrog AI to Unveil New Precision AI Capability

BullFrog AI to Unveil New Precision AI Capability New capabilities to be launched on March 25Unique technology bolsters BullFrog AI’s end-to-end AI intelligence workflow with a scenario-based decision engineAdvances current AI decision tools by clearly defining clinical trial strategies and building diversified, risk-balanced R&D portfolios GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into...

 PRESS RELEASE

BullFrog AI on Data Harmonization: The Hidden Prerequisite for Reliabl...

BullFrog AI on Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences White paper discusses how BullFrog AI’s bfPREP™ embodies data harmonization, enabling biopharma organizations to convert noisy, document-heavy data into standardized, AI-ready datasets GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, publishes a white paper titled, “Data H...

 PRESS RELEASE

BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase...

BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer Company’s bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI GAITHERSBURG, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into ...

 PRESS RELEASE

BullFrog AI Publishes Annual Letter to Shareholders

BullFrog AI Publishes Annual Letter to Shareholders Highlights significant progress in 2025 and outlines commercial priorities and potential catalysts entering 2026 GAITHERSBURG, Md., Dec. 30, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the release of its annual letter to shareholders, which highlights progress made during 2025 and outlines key priorities and po...

 PRESS RELEASE

BullFrog AI Publishes Whitepaper on AI in Bioinformatics: Turning Comp...

BullFrog AI Publishes Whitepaper on AI in Bioinformatics: Turning Complex Data into Actionable Insights New publication details how BullFrog Data Networks® and bfLEAP® technology address fundamental AI challenges in drug discovery and development GAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the publication of a new whitepaper titled “A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch